Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Bristol acquires fibrotic disease company Amira for $325mm up front

29 Mar 2016

Executive Summary

Marking its first foray into the fibrotic disease area, Bristol-Myers Squibb Co. is acquiring private Amira Pharmaceuticals Inc. (developing small molecules for disorders caused by inflammation) for $325mm up front and up to $150mm in earn-outs, in three increments of $50mm each. (One of the milestone payments is expected sometime this year.)
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By